A cost-utility analysis of antenatal screening to prevent congenital rubella syndrome.
In low vaccination coverage regions (LVR) in The Netherlands people often reject participation in the National Immunization Programme for religious reasons. During a rubella epidemic in 2004-2005, 32 pregnant women were notified with rubella, and 11 babies were born with defects related to maternal infection. This study presents a cost-utility analysis of a screening and vaccination programme for rubella focusing on three scenarios: (1) screening non-vaccinated pregnant women in LVR; (2) screening all pregnant women in LVR; (3) screening all non-vaccinated pregnant women in The Netherlands (including pregnant first-generation non-Western immigrant women). Cost-utility was estimated over a 16-year period which included two rubella outbreaks. Observed complications from the 2004-2005 epidemic were used to estimate average cost savings and quality-adjusted life-years (QALY) gained. The programme would be cost-effective (euro1100/QALY gained) when assuming an acceptability of vaccination of 20% in women belonging to orthodox protestant risk groups.
Lugnér
A K
AK
RIVM-Centre for Infectious Disease Control, Epidemiology and Surveillance Unit, Bilthoven, The Netherlands. anna.lugner@rivm.nl
Mollema
L
L
Ruijs
W L M
WL
Hahné
S J M
SJ
D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D004196:Disease Outbreaks / Q000191:economics / Q000517:prevention & control / Q000706:statistics & numerical data; D005260:Female; D005843:Geography; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008403:Mass Screening / Q000191:economics / Q000706:statistics & numerical data; D032541:Mass Vaccination / Q000191:economics* / Q000706:statistics & numerical data; D011247:Pregnancy; D011296:Prenatal Diagnosis / Q000191:economics*; D019057:Quality-Adjusted Life Years; D012410:Rubella Syndrome, Congenital / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control; D012411:Rubella Vaccine
D012411:Rubella Vaccine